Published in Br J Clin Pharmacol on February 01, 2011
Improved prediction of tacrolimus concentrations early after kidney transplantation using theory-based pharmacokinetic modelling. Br J Clin Pharmacol (2014) 1.38
PharmGKB summary: cyclosporine and tacrolimus pathways. Pharmacogenet Genomics (2013) 0.89
Importance of hematocrit for a tacrolimus target concentration strategy. Eur J Clin Pharmacol (2013) 0.88
A published pharmacogenetic algorithm was poorly predictive of tacrolimus clearance in an independent cohort of renal transplant recipients. Br J Clin Pharmacol (2013) 0.81
Conversion from twice- to once-daily tacrolimus in pediatric kidney recipients: a pharmacokinetic and bioequivalence study. Pediatr Nephrol (2014) 0.80
External evaluation of published population pharmacokinetic models of tacrolimus in adult renal transplant recipients. Br J Clin Pharmacol (2016) 0.79
Coadministration of liraglutide with tacrolimus in kidney transplant recipients: a case series. Diabetes Care (2013) 0.77
Population pharmacokinetics and Bayesian estimation of tacrolimus exposure in paediatric liver transplant recipients. Br J Clin Pharmacol (2014) 0.75
Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm (1981) 6.53
The effect of graft function on FK506 plasma levels, dosages, and renal function, with particular reference to the liver. Transplantation (1991) 3.14
Effect of hepatic dysfunction and T tube clamping on FK 506 pharmacokinetics and trough concentrations. Transplant Proc (1990) 2.60
Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin Pharmacokinet (2004) 2.58
Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther (2003) 2.09
Clinical pharmacokinetics of tacrolimus. Clin Pharmacokinet (1995) 1.96
Impact of cytochrome p450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients. Transplantation (2003) 1.83
Opportunities to optimize tacrolimus therapy in solid organ transplantation: report of the European consensus conference. Ther Drug Monit (2009) 1.68
Kidney function estimating equations: where do we stand? Curr Opin Nephrol Hypertens (2006) 1.53
CYP3A5 variant allele frequencies in Dutch Caucasians. Clin Chem (2002) 1.53
Racial differences in renal transplantation after immunosuppression with tacrolimus versus cyclosporine. FK506 Kidney Transplant Study Group. Transplantation (1998) 1.38
Pharmacokinetic interaction between corticosteroids and tacrolimus after renal transplantation. Nephrol Dial Transplant (2003) 1.34
Pharmacokinetics of tacrolimus in liver transplant patients. Clin Pharmacol Ther (1995) 1.33
AUC-guided dosing of tacrolimus prevents progressive systemic overexposure in renal transplant recipients. Kidney Int (2005) 1.30
An open-label, concentration-ranging trial of FK506 in primary kidney transplantation: a report of the United States Multicenter FK506 Kidney Transplant Group. Transplantation (1996) 1.27
Tacrolimus pharmacogenetics: the CYP3A5*1 allele predicts low dose-normalized tacrolimus blood concentrations in whites and South Asians. Transplantation (2005) 1.24
Pharmacokinetics of FK506 in liver transplant recipients after continuous intravenous infusion. J Clin Pharmacol (1993) 1.23
Population pharmacokinetics of tacrolimus in adult kidney transplant recipients. Clin Pharmacol Ther (2002) 1.21
Tacrolimus population pharmacokinetic-pharmacogenetic analysis and Bayesian estimation in renal transplant recipients. Clin Pharmacokinet (2009) 1.21
CYP3A5 and ABCB1 polymorphisms and tacrolimus pharmacokinetics in renal transplant candidates: guidelines from an experimental study. Am J Transplant (2006) 1.21
Contribution of CYP3A5 to the in vitro hepatic clearance of tacrolimus. Clin Chem (2005) 1.14
Explaining variability in tacrolimus pharmacokinetics to optimize early exposure in adult kidney transplant recipients. Ther Drug Monit (2009) 1.12
Beyond cyclosporine: a systematic review of limited sampling strategies for other immunosuppressants. Ther Drug Monit (2006) 1.10
Population pharmacokinetics and bioavailability of tacrolimus in kidney transplant patients. Br J Clin Pharmacol (2007) 1.08
Time-related clinical determinants of long-term tacrolimus pharmacokinetics in combination therapy with mycophenolic acid and corticosteroids: a prospective study in one hundred de novo renal transplant recipients. Clin Pharmacokinet (2004) 1.06
Pharmacokinetics of tacrolimus-based combination therapies. Nephrol Dial Transplant (2003) 1.06
Factors affecting the pharmacokinetics of tacrolimus in the first year after renal transplantation. European Tacrolimus Multicentre Renal Study Group. Transplant Proc (1998) 1.05
Effect of low- and high-fat meals on tacrolimus absorption following 5 mg single oral doses to healthy human subjects. J Clin Pharmacol (2001) 1.02
Abbreviated tacrolimus area-under-the-curve monitoring for renal transplant recipients. Am J Kidney Dis (2000) 0.95
A limited sampling strategy for tacrolimus in renal transplant patients. Br J Clin Pharmacol (2008) 0.94
Evaluation of a rapid micro-scale assay for tacrolimus by liquid chromatography-tandem mass spectrometry. Ann Clin Biochem (2002) 0.94
Effect of time of meal consumption on bioavailability of a single oral 5 mg tacrolimus dose. J Clin Pharmacol (2001) 0.92
Differences in oral FK506 dose requirements between adult and pediatric liver transplant patients. Transplantation (1993) 0.92
Time of drug administration, CYP3A5 and ABCB1 genotypes, and analytical method influence tacrolimus pharmacokinetics: a population pharmacokinetic study. Ther Drug Monit (2009) 0.91
Effect of race and immunosuppression in renal transplantation: three-year survival results from a US multicenter, randomized trial. FK506 Kidney Transplant Study Group. Transplant Proc (1998) 0.91
Immunosuppressive drug monitoring - what to use in clinical practice today to improve renal graft outcome. Transpl Int (2005) 0.90
Evaluation of a limited sampling strategy to estimate area under the curve of tacrolimus in adult renal transplant patients. Ther Drug Monit (2005) 0.88
Therapeutic drug monitoring of tacrolimus in clinical transplantation. Ther Drug Monit (1995) 0.88
Effect of breakfast on the oral bioavailability of tacrolimus and changes in pharmacokinetics at different times posttransplant in renal transplant recipients. Transplant Proc (1998) 0.88
Experience with FK506 in living-related liver transplantation. Transplantation (1993) 0.86
Lowered blood concentration of tacrolimus and its recovery with changes in expression of CYP3A and P-glycoprotein after high-dose steroid therapy. Transplantation (2002) 0.85
FK 506: monitoring in plasma or in whole blood? Transplant Proc (1991) 0.84
The roles of C4 and AUC0-4 in monitoring of tacrolimus in stable kidney transplant patients. Transplant Proc (2002) 0.83
C2 (2-h) levels are not superior to trough levels as estimates of the area under the curve in tacrolimus-treated renal-transplant patients. Nephrol Dial Transplant (2002) 0.83
Strategy of FK 506 therapy in liver transplant patients: effect of graft function. Transplant Proc (1991) 0.83
Evaluation of limited sampling strategies for tacrolimus. Eur J Clin Pharmacol (2007) 0.82
Trough levels of tacrolimus. Ther Drug Monit (2002) 0.82
Chronopharmacokinetics of tacrolimus in kidney transplant recipients: occurrence of acute rejection. J Clin Pharmacol (2003) 0.82
Effective oral administration of tacrolimus in renal transplant recipients. Clin Transplant (2001) 0.82
Pharmacokinetics of FK506 after intravenous and oral administration in patients awaiting renal transplantation. J Clin Pharmacol (1994) 0.81
Limited sampling strategy for simultaneous estimation of the area under the concentration-time curve of tacrolimus and mycophenolic acid in adult renal transplant recipients. Ther Drug Monit (2008) 0.81
Choosing the right dose of new immunossuppressive drugs for new populations: importance of pharmacokinetic studies. Transplant Proc (2001) 0.80
Circadian variation of tacrolimus disposition in liver allograft recipients. Transplantation (1996) 0.80
Pharmacokinetics of tacrolimus primary immunosuppression in kidney transplant recipients. Transplant Proc (2001) 0.79
Increased tacrolimus levels in a pediatric renal transplant patient attributed to chronic diarrhea. Pediatr Transplant (2000) 0.79
Tacrolimus dosing requirements in diabetic and nondiabetic patients calculated from pretransplantation data. Transplant Proc (1998) 0.79
Tacrolimus dose requirement in renal transplant recipients is significantly higher when used in combination with corticosteroids. Br J Clin Pharmacol (2003) 0.78
Influence of hepatitis C virus infection on FK 506 blood levels in renal transplant patients. Transplant Proc (1998) 0.77
Clinical use and bioavailability of tacrolimus in heart-lung and double lung transplant recipients with cystic fibrosis. Transplant Proc (1998) 0.77
Effect of bile flow on the absorption of tacrolimus in liver allograft transplantation. Transplant Proc (2002) 0.77
Comparison of two population pharmacokinetic programs, NONMEM and P-PHARM, for tacrolimus. Eur J Clin Pharmacol (2002) 0.76
Apparently increased trough levels of tacrolimus caused by acute infantile diarrhea in two infants with biliary atresia after liver transplantation. Acta Paediatr Jpn (1996) 0.76
Comparative tacrolimus pharmacokinetics: normal versus mildly hepatically impaired subjects. J Clin Pharmacol (2001) 0.76
Recurrent HCV infection reduces the requirement for tacrolimus after liver transplantation. Transplant Proc (2001) 0.76
Optimal time points for the prediction of the area-under-the-curve in liver transplant patients receiving tacrolimus. Transplant Proc (1998) 0.76
Peritoneal dialysis-related infections recommendations: 2010 update. Perit Dial Int (2010) 12.06
A randomized, controlled trial of early versus late initiation of dialysis. N Engl J Med (2010) 10.33
A randomized trial of a single dose of oral dexamethasone for mild croup. N Engl J Med (2004) 5.02
Epinephrine and dexamethasone in children with bronchiolitis. N Engl J Med (2009) 4.35
ISPD position statement on reducing the risks of peritoneal dialysis-related infections. Perit Dial Int (2011) 3.88
Comparison of the 20-hour intravenous and 72-hour oral acetylcysteine protocols for the treatment of acute acetaminophen poisoning. Ann Emerg Med (2009) 3.67
Clinical practice guideline: the diagnosis, management, and prevention of bronchiolitis. Pediatrics (2014) 3.52
Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials. BMJ (2008) 3.35
Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease. Ann Intern Med (2010) 2.97
Cost-effectiveness of epinephrine and dexamethasone in children with bronchiolitis. Pediatrics (2010) 2.68
Chronic kidney disease and automatic reporting of estimated glomerular filtration rate: revised recommendations. Med J Aust (2007) 2.68
Cost-effectiveness of initiating dialysis early: a randomized controlled trial. Am J Kidney Dis (2011) 2.62
Clinical pharmacokinetics of metformin. Clin Pharmacokinet (2011) 2.59
Conditional weighted residuals (CWRES): a model diagnostic for the FOCE method. Pharm Res (2007) 2.51
HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst Rev (2014) 2.35
The effect of obesity on renal transplant outcomes. Transplantation (2002) 2.29
HMG CoA reductase inhibitors (statins) for dialysis patients. Cochrane Database Syst Rev (2013) 2.21
Relationship between dialysis modality and mortality. J Am Soc Nephrol (2008) 2.06
Biological variation of high sensitivity cardiac troponin-T in stable dialysis patients: implications for clinical practice. Clin Chem Lab Med (2015) 1.98
Is mycophenolate mofetil less safe than azathioprine in elderly renal transplant recipients? Transplantation (2002) 1.98
Dialysis modality preference of patients with CKD and family caregivers: a discrete-choice study. Am J Kidney Dis (2012) 1.97
Staphylococcus aureus peritonitis in Australian peritoneal dialysis patients: predictors, treatment, and outcomes in 503 cases. Perit Dial Int (2010) 1.89
Interleukin-1beta induces human proximal tubule cell injury, alpha-smooth muscle actin expression and fibronectin production. Kidney Int (2002) 1.84
Activation of ERK in renal fibrosis after unilateral ureteral obstruction: modulation by antioxidants. Kidney Int (2005) 1.83
Prevalence and correlates of self-reported sexual dysfunction in CKD: a meta-analysis of observational studies. Am J Kidney Dis (2010) 1.81
Glucocorticoids for acute viral bronchiolitis in infants and young children. Cochrane Database Syst Rev (2013) 1.77
The impact of neutral-pH peritoneal dialysates with reduced glucose degradation products on clinical outcomes in peritoneal dialysis patients. Kidney Int (2013) 1.75
Clinical practice guidelines for peritoneal access. Perit Dial Int (2010) 1.71
Corynebacterium peritonitis in Australian peritoneal dialysis patients: predictors, treatment and outcomes in 82 cases. Nephrol Dial Transplant (2009) 1.68
The honeypot study protocol: a randomized controlled trial of exit-site application of medihoney antibacterial wound gel for the prevention of catheter-associated infections in peritoneal dialysis patients. Perit Dial Int (2009) 1.66
Biocompatible dialysis fluids for peritoneal dialysis. Cochrane Database Syst Rev (2014) 1.63
Intradermal versus intramuscular hepatitis B vaccination in hemodialysis patients: a prospective open-label randomized controlled trial in nonresponders to primary vaccination. Am J Kidney Dis (2009) 1.61
Oxidative stress, anti-oxidant therapies and chronic kidney disease. Nephrology (Carlton) (2012) 1.61
Peritoneal small solute clearance is nonlinearly related to patient survival in the Australian and New Zealand peritoneal dialysis patient populations. Perit Dial Int (2009) 1.61
A risk quantification instrument for acute acetaminophen overdose patients treated with N-acetylcysteine. Ann Emerg Med (2005) 1.60
Predictors of renal recovery in Australian and New Zealand end-stage renal failure patients treated with peritoneal dialysis. Perit Dial Int (2007) 1.59
Rapid viral diagnosis for acute febrile respiratory illness in children in the Emergency Department. Cochrane Database Syst Rev (2009) 1.58
Erythropoietin protects against ischaemic acute renal injury. Nephrol Dial Transplant (2004) 1.56
Microbiology and outcomes of peritonitis in Australian peritoneal dialysis patients. Perit Dial Int (2011) 1.56
Prevalence of depression in chronic kidney disease: systematic review and meta-analysis of observational studies. Kidney Int (2013) 1.52
HMG CoA reductase inhibitors (statins) for kidney transplant recipients. Cochrane Database Syst Rev (2014) 1.52
HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst Rev (2009) 1.52
The effect of oral iron admiinistration on mycophenolate mofetil absorption in renal transplant recipients: a randomized, controlled trial. Transplantation (2004) 1.52
High membrane transport status on peritoneal dialysis is not associated with reduced survival following transfer to haemodialysis. Nephrol Dial Transplant (2007) 1.51
Predictors and outcomes of fungal peritonitis in peritoneal dialysis patients. Kidney Int (2009) 1.49
Effects of uric acid-lowering therapy on renal outcomes: a systematic review and meta-analysis. Nephrol Dial Transplant (2013) 1.47
The frequency of complications associated with the use of multiple-dose activated charcoal. Ann Emerg Med (2003) 1.47
FTY720, a synthetic sphingosine 1 phosphate analogue, inhibits development of atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation (2007) 1.46
Human neutrophil clearance of bacterial pathogens triggers anti-microbial γδ T cell responses in early infection. PLoS Pathog (2011) 1.46
Practice variations in the treatment of febrile infants among pediatric emergency physicians. Pediatrics (2009) 1.45
Nebulized epinephrine for croup in children. Cochrane Database Syst Rev (2011) 1.43
Higher rate and earlier peritonitis in Aboriginal patients compared to non-Aboriginal patients with end-stage renal failure maintained on peritoneal dialysis in Australia: analysis of ANZDATA. Nephrology (Carlton) (2005) 1.43
Factors influencing patient choice of dialysis versus conservative care to treat end-stage kidney disease. CMAJ (2012) 1.43
Obesity is associated with worse peritoneal dialysis outcomes in the Australia and New Zealand patient populations. J Am Soc Nephrol (2003) 1.41
The Initiating Dialysis Early and Late (IDEAL) study: study rationale and design. Perit Dial Int (2004) 1.40
Internal standard selection for immunosuppressant drugs measured by high-performance liquid chromatography tandem mass spectrometry. Ther Drug Monit (2007) 1.39
Patient management by cyclosporine C2 monitoring: not enough science yet to justify the practice. Transplantation (2003) 1.38
Obesity is a risk factor for peritonitis in the Australian and New Zealand peritoneal dialysis patient populations. Perit Dial Int (2004) 1.38
Croup in the paediatric emergency department. Paediatr Child Health (2007) 1.38
Improved prediction of tacrolimus concentrations early after kidney transplantation using theory-based pharmacokinetic modelling. Br J Clin Pharmacol (2014) 1.38
Higher peritoneal transport status is associated with higher mortality and technique failure in the Australian and New Zealand peritoneal dialysis patient populations. J Am Soc Nephrol (2005) 1.37
A randomized trial of dietary sodium restriction in CKD. J Am Soc Nephrol (2013) 1.36
Length of time on peritoneal dialysis and encapsulating peritoneal sclerosis: position paper for ISPD. Perit Dial Int (2009) 1.34
Review article: Hepatitis B and dialysis. Nephrology (Carlton) (2010) 1.32
Pseudomonas peritonitis in Australia: predictors, treatment, and outcomes in 191 cases. Clin J Am Soc Nephrol (2009) 1.31
Culture-negative peritonitis in peritoneal dialysis patients in Australia: predictors, treatment, and outcomes in 435 cases. Am J Kidney Dis (2010) 1.31
Molecular cell biology of androgen receptor signalling. Int J Biochem Cell Biol (2009) 1.30
Corticosteroid therapy in IgA nephropathy. J Am Soc Nephrol (2012) 1.30
Metabolic syndrome in severe chronic kidney disease: Prevalence, predictors, prognostic significance and effects of risk factor modification. Nephrology (Carlton) (2007) 1.28
The impact of automated eGFR reporting and education on nephrology service referrals. Nephrol Dial Transplant (2008) 1.27
Predictors of decline of residual renal function in new peritoneal dialysis patients. Perit Dial Int (2003) 1.26
Coagulase-negative staphylococcal peritonitis in Australian peritoneal dialysis patients: predictors, treatment and outcomes in 936 cases. Nephrol Dial Transplant (2010) 1.24
Remote indigenous peritoneal dialysis patients have higher risk of peritonitis, technique failure, all-cause and peritonitis-related mortality. Nephrol Dial Transplant (2011) 1.23
Predictors, treatment, and outcomes of non-Pseudomonas Gram-negative peritonitis. Kidney Int (2010) 1.22
Population pharmacokinetics of tacrolimus in adult kidney transplant recipients. Clin Pharmacol Ther (2002) 1.21
Changes in serum prolactin, sex hormones and thyroid function with alternate nightly nocturnal home haemodialysis. Nephrology (Carlton) (2012) 1.20
Population pharmacokinetics of tacrolimus in pediatric hematopoietic stem cell transplant recipients: new initial dosage suggestions and a model-based dosage adjustment tool. Ther Drug Monit (2009) 1.19
A systematic review on the diagnosis of pediatric bacterial pneumonia: when gold is bronze. PLoS One (2010) 1.18
Streptococcal peritonitis in Australian peritoneal dialysis patients: predictors, treatment and outcomes in 287 cases. BMC Nephrol (2009) 1.16
Peritoneal dialysis practice in Australia and New Zealand: a call to action. Nephrology (Carlton) (2011) 1.16
Polymicrobial peritonitis in peritoneal dialysis patients in Australia: predictors, treatment, and outcomes. Am J Kidney Dis (2009) 1.15
Glucocorticoids for croup. Cochrane Database Syst Rev (2011) 1.13
Practice variation among pediatric emergency departments in the treatment of bronchiolitis. Acad Emerg Med (2004) 1.12
Outcomes of transplants from patients with small renal tumours, live unrelated donors and dialysis wait-listed patients. Transpl Int (2009) 1.12
Increased targeting of cardiovascular risk factors in patients with chronic kidney disease does not improve atheroma burden or cardiovascular function. Am Heart J (2006) 1.12
Toward better outcomes with tacrolimus therapy: population pharmacokinetics and individualized dosage prediction in adult liver transplantation. Liver Transpl (2003) 1.11
Anti-angiogenic actions of pyrrolidine dithiocarbamate, a nuclear factor kappa B inhibitor. Angiogenesis (2009) 1.11